- In June 2023, Pfizer Inc. and OPKO Health Inc. achieved FDA approval for NGENLA (somatrogon‑ghla), the first once-weekly human growth hormone analog for pediatric use. This approval marks a breakthrough, reducing injection frequency from daily to weekly while maintaining comparable efficacy in promoting height velocity in children aged three and older
- In April 2023, Novo Nordisk announced expanded FDA approval of Sogroya (somapacitan‑beco) for use in pediatric growth hormone deficiency. Originally approved for adults in 2020, this once-weekly treatment is now accessible for children, backed by the REAL4 Phase III trial showing effectiveness and safety similar to daily growth hormone injections
